Chief Executive Officer, Instylla
Appears in 1 story
Leading commercial launch after two FDA approvals
The FDA on October 29 approved Instylla's Embrace hydrogel embolic system for a second indication: stopping peripheral arterial bleeds in vessels up to 6 millimeters. It is the first liquid embolic cleared for both arterial bleeding and hypervascular tumor embolization, and it is on the US market now.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
